In vitro activity of ertapenem against anaerobes isolated from the respiratory tract

Pathologie Biologie

Volumn 51, Issue 8-9, 2003, Pages 508-511

  Piérard, Denis ^a   Wybo, Ingrid ^a   Vandoorslaer, Kristof ^a   Roebben, Elly ^a   Rosseel, Paul ^a   Lauwers, Sabine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Anaerobes; Carbapenems; Ertapenem; Pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFTRIAXONE; CLINDAMYCIN; ERTAPENEM; IMIPENEM; MEROPENEM; MOXIFLOXACIN; PENICILLIN G;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONFERENCE PAPER; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION; SPECIES;

EID: 17644439877     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(03)00152-4     Document Type: Conference Paper

References (11)

1. Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002;24(11):1770-85.
2. Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs 2001;10(6):1157-66.
3. Goldstein EJ, Citron DM, Vreni MC, Warren Y, Tyrrell KL. Comparative in vitro activities of ertapenem (MK-0826) against 1001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000;44(9):2389-94.
4. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez H. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob Agents Chemother 2002;46(4):1136-40.
5. Hoellman DB, Kelly LM, Credito K, Anthony L, Ednie LM, Jacobs MR, et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother 2002;46(1):220-4.
6. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45(6):1860-7.
7. Piérard D, De Meyer A, Rosseel P, Lauwers S. Use of the E-test for determining antimicrobial susceptibility of anaerobic bacteria. Pathol Biol (Paris) 1996;44(5):358-62.
8. Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué 2003. Paris: Société Française de Microbiologie; 2003.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing of anaerobic bacteria: Informational Supplement. Document M100-S13. Wayne, Pennsylvania, USA: NCCLS; 2003.
10. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34(8):1076-83.
11. Levison ME. Anaerobic pleuropulmonary infection. Curr Opin Infect Dis 2001;14(2):187-91.